Safety and Efficacy Findings From a Phase Ib/ <scp>II</scp> Study of <scp>ASP</scp> ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

20257 citationsJournal Articlehybrid Open Access

Authors

ASP-1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.

Published in: Head & Neck

Volume 48, Issue 1, pp. 160-174

Field-Weighted Citation Impact: 7.11